A Phase 1 Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies
Latest Information Update: 20 Jun 2023
At a glance
- Drugs CDX 527 (Primary)
- Indications Colorectal cancer; Glioblastoma; Malignant melanoma; Ovarian cancer; Pancreatic cancer; Prostate cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Celldex Therapeutics Inc
Most Recent Events
- 16 Jun 2023 Status changed from active, no longer recruiting to completed.
- 15 Mar 2023 Planned End Date changed from 1 Mar 2023 to 1 Apr 2023.
- 15 Mar 2023 Planned primary completion date changed from 1 Jan 2023 to 1 Apr 2023.